John K Camoriano, MD

  • 2713 Citations
  • 27 Scopus h-Index
1982 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where John K Camoriano is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 24 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 2713 Citations
  • 27 Scopus h-Index
  • 45 Article
  • 4 Letter

Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis

Bubik, R. J., Barth, D. M., Hook, C., Wolf, R. C., Muth, J. M., Mara, K., Patnaik, M. S., Pruthi, R. K., Marshall, A. L., Litzow, M. R., Elliott, M. A., Hogan, W. J., Shah, M. V., Begna, K. H., Alkhateeb, H., Pardanani, A., Ashrani, A. A., Call, T. G., Rivera, C. E., Camoriano, J. K. & 3 others, Go, R. S., Wolanskyj-Spinner, A. P. & Parikh, S. A., Jun 6 2020, In : Leukemia and Lymphoma. 61, 7, p. 1592-1600 9 p.

Research output: Contribution to journalArticle

  • PET/TC con 18F-FDG en la detección de adenocarcinoma oculto de vesícula biliar que se presenta como tumores de Krukenberg ováricos bilaterales

    Translated title of the contribution: 18F-FDG PET/CT in detection of occult gallbladder adenocarcinoma presenting as bilateral ovarian Krukenberg tumorsJamison, D. K., Butler, K. A., Stucky, C. C. H., Camoriano, J. K. & Yang, M., Jan 1 2018, (Accepted/In press) In : Revista Espanola de Medicina Nuclear e Imagen Molecular.

    Research output: Contribution to journalArticle

    A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy

    Rosenthal, A., Dueck, A., Ansell, S. M., Gano, K., Conley, C., Nowakowski, G. S., Camoriano, J. K., Leis, J. F., Mikhael, J. R., Stewart, A. K., Inwards, D., Dingli, D. M., Kumar, S. K., Noel, P., Gertz, M., Porrata, L., Russell, S. J., Colgan, J., Fonseca, R., Habermann, T. M. & 6 others, Kapoor, P., Buadi, F., Leung, N., Tiedemann, R., Witzig, T. E. & Reeder, C., May 1 2017, In : American Journal of Hematology. 92, 5, p. 467-472 6 p.

    Research output: Contribution to journalArticle

  • 5 Scopus citations

    Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis

    Gowin, K., Kosiorek, H., Dueck, A., Mascarenhas, J., Hoffman, R., Reeder, C., Camoriano, J., Tibes, R., Gano, K., Palmer, J. & Mesa, R., Sep 1 2017, In : Leukemia Research. 60, p. 31-35 5 p.

    Research output: Contribution to journalArticle

  • 12 Scopus citations

    Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial

    Gowin, K., Jain, T., Kosiorek, H., Tibes, R., Camoriano, J. K., Palmer, J. & Mesa, R., Mar 1 2017, In : Leukemia Research. 54, p. 73-77 5 p.

    Research output: Contribution to journalArticle

  • 12 Scopus citations